Business
Novartis Experimental Prostate Cancer Drug Shows Promising Late-Stage Trial Results
Novartis reported positive late-stage trial results for its experimental prostate cancer treatment, signaling a potential new therapeutic option for patients with advanced disease. The data, released on May 31, 2026, showed the drug met its primary efficacy endpoints in the Phase III study.
Trial Details and Efficacy
The investigational therapy demonstrated a statistically significant improvement in radiographic progression-free survival compared to standard of care. The study enrolled patients with metastatic castration-resistant prostate cancer who had previously received at least one prior systemic therapy. Novartis plans to submit the results for regulatory review in the coming months.Safety Profile
Treatment-related adverse events were consistent with those observed in earlier-stage trials. No new safety signals were identified, and the discontinuation rate due to side effects was comparable to the control arm. Full safety data will be presented at an upcoming medical conference.Market Context
- USD/RUB: 71.02 (change: -0.35)
- EUR/RUB: 82.64 (change: -1.05)
- Bitcoin: $73,851 (24-hour change: +0.5%)
- Crude oil: approximately $72 per barrel